CTI BIOPHARMA
CTI BioPharma Corp. a biopharmaceutical company, develops, acquires, and commercializes oncology products for cancer treatment. Its development portfolio includes Pixantrone, a phase III trial product, for non-Hodgkin's lymphoma; Brostallicin, which is in first-line Phase II study for the treatment of sarcoma; and OPAXIO, a chemotherapeutic agent for the potential treatment of non-small cell lung, ovarian, and other cancers. It has collaboration and licensing arrangements with Novartis International Pharmaceutical, Ltd.; and PG-TXL Company, L.P.
CTI BIOPHARMA
Industry:
Biotechnology Health Care Therapeutics
Founded:
1991-01-01
Address:
Seattle, Washington, United States
Country:
United States
Website Url:
http://www.ctibiopharma.com
Total Employee:
251+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
185.76 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Agile Therapeutics
Agile Therapeutics is pharmaceutical company developing contraceptive healthcare products for women.
Calithera Biosciences
Calithera Biosciences is a pharmaceutical company developing novel small molecule therapeutics for the treatment of cancer.
Chiasma
Chiasma is a biopharmaceutical company developing oral drugs for the treatment of orphan diseases.
Epizyme
Epizyme is a biopharmaceutical company focusing on treatments for blood cancer and tumors.
Galera Therapeutics
Galera Therapeutics develops therapeutic agents for preventing damage to normal tissues during the radiation treatment of cancer.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
DRI Healthcare Trust
DRI Healthcare Trust investment in Post-IPO Debt - CTI BioPharma
New Enterprise Associates
New Enterprise Associates investment in Post-IPO Equity - CTI BioPharma
Hercules Capital
Hercules Capital investment in Post-IPO Debt - CTI BioPharma
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2016-02-10 | Biowatch | CTI BioPharma investment in Grant - Biowatch | 800 K CHF |
Newest Events participated
Official Site Inspections
http://www.ctibiopharma.com Semrush global rank: 1.91 M Semrush visits lastest month: 11.4 K
- Host name: 141.193.213.20
- IP address: 141.193.213.20
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
